ELIXA [22] | LEADER [24] | SUSTAIN-6 [25] | Harmony outcomes [30] | PIONEER 6 [32] | REWIND [34] | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lixisenatide | Placebo | Liraglutide | Placebo | Semaglutide | Placebo | Exenatide | Placebo | Albiglutide | Placebo | Semaglutide | Placebo | Dulaglutide | Placebo | |
N | 3034 | 3034 | 4668 | 4672 | 1648 | 1649 | 7356 | 7396 | 4731 | 4732 | 1591 | 1592 | 4949 | 4952 |
MACE (per 100 patient-yr) | 6.40 | 6.30 | 3.40* | 3.90 | 3.24* | 4.44 | 3.70 | 4.00 | 4.57* | 5.87 | 2.90* | 3.70 | 2.35* | 2.66 |
CV death | 2.30 | 2.40 | 1.20* | 1.60 | 1.29 | 1.35 | 1.40 | 1.50 | 1.61 | 1.72 | 0.70 | 1.40 | 1.22 | 1.34 |
Non-fatal MI | 4.20 | 4.10 | 1.60 | 1.80 | 1.40 | 1.92 | (2.10) (fatal or nonfatal) | (2.10) (fatal or nonfatal) | (2.43) * (fatal or nonfatal) | (3.26) (fatal or nonfatal) | 1.80 | 1.50 | 0.80 | 0.84 |
Non-fatal stroke | 1.00 | 0.90 | 0.90 | 1.00 | 0.80* | 1.31 | (0.80) (fatal or nonfatal) | (0.90) (fatal or nonfatal) | (1.25) (fatal or nonfatal) | (1.45) (fatal or nonfatal) | 0.60 | 0.80 | 0.52* | 0.69 |
UA | 0.20 | 0.10 | (0.7) | (0.7) | (0.65) | (0.80) | N/A | N/A | N/A | N/A | (0.50) | (0.30) | (0.34) | (0.30) |